Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Design Therapeutics, Inc. (DSGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
4
| LAPPE RODNEY W (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Bought 21,000 shares
@ $2.347, valued at
$49.3k
|
|
| 08/25/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results|
Docs:
|
"DESIGN THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $ 17,064 $ 11,295 $ 32,794 $ 20,054 General and administrative 5,532 4,344 11,453 8,955 Total operating expenses 22,596 15,639 44,247 29,009 Loss from operations Other income, net 2,659 640 5,016 745 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares of common stock outstanding, basic and diluted 55,948,990 55,670,780 55,928,625 55,589,510 DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS June 30, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 303,088 $ 330,387 Prepaid expense and other current assets 2,957 4,732 Total curren..." |
|
| 06/02/2023 |
4
| George Simeon (10% Owner) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| Prasad Deepa (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| Schmid John P. (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| Xu Stella (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| William Arsani (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| Berger Heather A. (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/02/2023 |
4
| LAPPE RODNEY W (Director) has filed a Form 4 on Design Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $5.63, valued at
$84.5k
|
|
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"DESIGN THERAPEUTICS, INC. CONDENSED BALANCE SHEETS March 31, December 31, 2023 2022 Assets Current assets: Cash, cash equivalents and investment securities $ 315,392 $ 330,387 Prepaid expense and other current assets 3,547 4,732 Total current assets 318,939 335,119 Property and equipment, net 1,905 1,947 Right-of-use asset, related party 3,447 3,612 Other assets 452 459 Total assets $ 324,743 $ 341,137 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,744 $ 3,025 Accrued expenses and other current liabilities 6,303 7,751 Total current liabilities 9,047 10,776 Operating lease liability, net, related party 2,878 3,051 Total liabilities 11,925 13,827 Total stockholders’ equity 312,818 327,310 Total liabilities and stockholders’ equity $ 324,743 $ 341,137 DESIGN TH..." |
|
| 04/13/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/13/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/13/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.1% stake in Design Therapeutics, Inc. |
| 03/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.2% stake in Design Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
SC 13G
| BlackRock Inc. reports a 6.3% stake in DESIGN THERAPEUTICS INC |
| 12/22/2022 |
SC 13D/A
| SR One Capital Fund I Aggregator LP reports a 11.7% stake in Design Therapeutics, Inc. |
| 12/22/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|